Aerogen Inc (1039160) SEC Filing 10-Q Quarterly report for the period ending Thursday, June 30, 2005

Aerogen Inc

CIK: 1039160


Exhibit 99.1





Robert S. Breuil



(650) 864-7431



Mountain View, CA, May 13, 2005 — Aerogen, Inc. (Nasdaq: AEGN) today announced financial results for the three months ended March 31, 2005.  The net loss attributable to common stockholders for the three months ended March 31, 2005 was $0.8 million, or $0.13 per share, compared with a net loss of $11.9 million, or $2.66 per share, for the same period in 2004.


The results for the three months ended March 31, 2004 included a charge of $6.4 million, or $1.45 per share, reflecting a deemed dividend imputed from the difference between the allocated proceeds and the conversion value of the Company’s Series A-1 Convertible Preferred Stock that was issued during the first half of 2004.  There were no deemed dividends in the three months ended March 31, 2005.


The terms of the Series A-1 Convertible Preferred Stock provide for a dividend, at the rate of 6% per year, to be paid quarterly in cash or Aerogen common stock, at the Company’s election, to each holder of Series A-1 Convertible Preferred Stock.  During the three months ended March 31, 2005 and 2004, the Company elected to pay this dividend in Aerogen common stock, resulting in charges related to ordinary dividends of $0.4 million, or $0.07 per share, and $20,000, or $0.00 per share, respectively.


The gain from the decline in the fair market value of the liability associated with outstanding warrants was $4.0 million for the three months ended March 31, 2005, as compared to a loss of $1.1 million for the same period in 2004.  The gain in 2005 was due to a decline in the market value of the Company’s common stock in the first quarter of 2005 while the loss in 2004 was due to an increase in the market value of its common stock in the first quarter of 2004.


Aerogen’s cash balance as of March 31, 2005 was $13.6 million.  Based on current expectations of sales and royalty levels and operating costs, existing capital resources will not enable the Company to maintain current and planned operations beyond the first quarter of 2006; however, if certain expected product sales and/or royalties are not realized, the current cash balance may not sustain planned operations beyond the middle of the fourth quarter of 2005. The Company is pursuing a number of alternatives to maximize stockholder value, including strategic transactions, collaborative partnerships and the licensing or sale of certain of our intellectual property. If these efforts are not successful, the Company will need to raise additional capital before the end of 2005 in order to continue operations. Licensing or collaborative arrangements, if necessary to raise additional funds, may require Aerogen to relinquish rights to certain of its products or technologies, or desirable marketing territories, or all of these.


Revenues for the three months ended March 31, 2005 were $1.6 million, compared with $1.1 million for the same period in 2004.  The 45% increase in revenues for the three-month period ending March 31, 2005, as compared with the same period in 2004, primarily resulted from an increase in product sales of the Aeroneb® Professional Nebulizer System (“Aeroneb Pro”) and royalties associated with a large consumer products company’s sales of an air freshener incorporating our aerosol generator technology.  The increase in Aeroneb Pro sales was slightly offset by a decrease in the sales of our OnQ® Aerosol Generators to Evo Medical Solutions (“Evo”) (formerly Medical Industries America) in the three months ended March 31, 2005, as compared to the same period in 2004.  There were no shipments to Evo during January or



— more —


The following information was filed by Aerogen Inc on Wednesday, May 18, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aerogen Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aerogen Inc.


Assess how Aerogen Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aerogen Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1039160
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-05-034483
Submitted to the SEC: Wed Jul 27 2005 5:16:18 PM EST
Accepted by the SEC: Wed Jul 27 2005
Period: Thursday, June 30, 2005
Industry: Surgical And Medical Instruments And Apparatus

External Resources:

Bookmark the Permalink: